INTERVIEW: Scott Reese, CEO at US-based C-Beyond Health, says patient-doctor dialog is critical to successful treatment with CBD.
HempToday: You describe C-Beyond Health as being in the “patient directed” cannabinoid market. What does that really mean?
Scott Reese: First off. CBD is certainly the most prevalent and recognizable of the hemp derived cannabinoids. However the future lies in exacting combinations of the right cannabinoids in the right ratios to achieve health outcomes for particular conditions. “Patient directed,” to us, means bringing forth advanced botanical and medicinal chemistry solutions using the right cannabinoids to treat particular conditions. We start with patient needs assessments as the first phase of our product development cycle.